CA9 and renal cell carcinoma: Besides CAIX, oncofetal antigen 5T4 (with overexpression found in over 75% of RCC patient samples) [22] and the CD70 (overexpressed in about 40% of RCC patients) [86, 88, 136], are relevant targets to be further explored for the development of new cell immunotherapies for RCC management.